Vision and Mission
Board of Directors
Pipeline and Major Products
Presentations and Webcasts
Announcements and Circulars
Financial Reports and Listing Documents
IR Contact and Email Alert
Everest Medicines Appoints Wende Chen as Chief Commercial Officer
Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan
Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA™ (Eravacycline) for Complicated Intra-Abdominal Infections (cIAI)
Everest Medicines Subsidiary Acquires Exclusive Worldwide License to Develop and Commercialize Clinical Stage Novel FGFR4 Kinase Inhibitor
Ian Woo Joins Everest Medicines as President and Chief Financial Officer; Named Managing Director of C-Bridge Capital
Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Admin
Tetraphase Pharmaceuticals Enters Into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China.
Arena eligible to receive up to $224M, including upfront and milestone payments, in addition to royalties.
C-Bridge Capital specializes in the growing Chinese health care market and is using its expertise to identify emerging industry leaders and bring global innovation into China.